```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory compound extensively used in cardiovascular research . This monoclonal antibody fragment selectively targets the glycoprotein IIb/IIIa complex on platelets , blocking platelet aggregation . Consequently , it's commonly employed as a method to copyrightine the mechanisms underlying coagulation and to evaluate the performance of anticoagulant drugs . Distribution is typically restricted to Abciximab bulk academic settings.
```
Abciximab Research: Utilizing C7E3 Antibody and 143653-53-6 in Research Investigations
Ongoing investigation into abciximab, a antiplatelet agent, frequently incorporates the monoclonal antigen C7E3 and the molecule identified as 143653-53-6. These materials are crucial for analyzing abciximab's mechanism of action, determining its efficacy in different patient populations, and elucidating potential predictors of patient outcome. Continued investigation leveraging these specific reagents is expected to provide valuable data for improving clinical applications concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Scientific Avenues with Abciximab 143653-53-6 using C7E3
Recent studies indicate that the drug (identified as 143653-53-6) holds significant scientific potential, particularly when paired with a C7E3 construct. Initial findings suggested that this combination might improve patient responses in several heart-related settings. Further investigation is centered on understanding the specific mode of action between Abciximab and C7E3, including assessment of thrombocyte clumping and arterial safeguarding.
- Current study endeavors seek to refine delivery strategies.
- Preclinical systems are being applied to further assess the hypotheses.
- Clinical trials will be essential to fully determine patient benefit.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers requiring C7E3 for experimental research should carefully consider quality and defined parameters . The compound is typically provided as a solid powder and thorough analytical data including verification by mass spectrometry , potency assays, and endotoxin testing are available. Verify the supplier's CoA outlines defined limits for contaminants and conforms to relevant quality assurance standards .
High-Purity ReoPro Details & Availability
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the product number 143653-53-6, requires careful consideration of its origin . This agent is widely utilized in in vitro investigations , particularly those related to platelet adhesion and clotting . Existing vendors offer this reagent in varying quantities , typically ranging from mg to significant commercial quantities . Please recommend reviewing the report of testing to verify integrity and suitability for your specific purpose. Furthermore , confirm the shelf life date before procuring to maintain maximum efficacy .
- Standard Purity: >95%
- Storage Conditions: -20°C and appropriate conditions
- Use : Platelet Clumping Blocking Studies